As the year comes to a close, we would like to recognize all of the people who have contributed to the growth and continued success of Contemporary OB/GYN.
Catherine Y. Spong, MD
Since joining Contemporary OB/GYN in April as Editor-in-Chief, Catherine Y. Spong, MD has gracefully and skillfully led our team through a year no one saw coming.
Jon I. Einarsson, MD, MPH, PHD
Thank you to our Deputy Editor, Jon I. Einarsson, MD, MPH, PHD, for his continued support and valuable contributions.
Thank you to the esteemed members of our Editorial Advisory Board; We appreciate all of the work you do. We would also like to recognize the Board’s newest members who joined with enthusiasm, despite a global pandemic: Yalda Afshar, MD, PHD, Christine Isaacs, MD, and Laura Riley, MD. Welcome to the team!
Thank you to former Editorial Advisory Board member Sharon T. Phelan, MD, for her keen insights and expertise, and to Judith M. Orvos, long-time editorial consultant, whose contributions have helped shape the magazine into what it is today.
We are excited to begin another year with such a distinguished team behind us, and with you, our readers, to join the conversation as learners, practitioners and educators. We are eager to begin another wonderful year with you.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More